Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › alendronate

alendronate

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of alendronate

26 trials tracked of alendronate: 12 in phase 3 or 4 and 4 with published results. The most-cited published study has 1507 citations.

26Trials tracked
12Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 4 Phase 3 8 Phase 2 10 Other / NA 4
  1. Phase 3 Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis Completed · 1,507 cited
  2. Phase 3 Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis Completed · 206 cited
  3. Phase 3 Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation Completed · 41 cited
  4. Phase 3 Alendronate to Prevent Loss of Bronchoprotection in Asthma Completed · 11 cited
  5. Phase 4 Bisphosphonate Therapy for Osteogenesis Imperfecta Completed
  6. Phase 4 Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study Completed
Show 20 more trials
  1. Phase 4 A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease. Completed
  2. Phase 4 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women Completed
  3. Phase 3 Denosumab Adherence Preference Satisfaction Study Completed
  4. Phase 3 Study of Transitioning From Alendronate to Denosumab Completed
  5. Phase 3 Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis Completed
  6. Phase 3 A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density. Completed
  7. Phase 2 Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis Completed
  8. Phase 2 Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents Completed
  9. Phase 2 Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density Completed
  10. Phase 2 A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density Completed
  11. Phase 2 MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) Completed
  12. Phase 2 Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide Completed
  13. Phase 2 Bisphosphonates for Prevention of Post-Denosumab Bone Loss Completed
  14. Phase 2 Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density Completed
  15. Phase 2 Romosozumab in Women With Chronic SCI Completed
  16. Phase 2 Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis Completed
  17. N/A Renal Osteodystrophy: An Individual Management Approach Completed
  18. N/A Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants Completed
  19. N/A Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352) Completed
  20. N/A Texture Analysis for Postmenopausal Osteoporosis Completed

Showing the 26 most-cited and recently-updated of 26 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Potent bisphosphonate therapy reduces incident vertebral fractures by 71% after denosumab discontinuation
Orthopedics & Sports Medicine Meta-analysis
Potent bisphosphonate therapy reduces incident vertebral fractures by 71% after denosumab discontinuation Potent bisphosphonates may lower fracture risk after denosumab treatment stops
This meta-analysis of 683 adults with osteoporosis or low bone mass found that potent bisphosphonate therapy significantly reduced incident …
Patients with osteoporosis may have a lower risk of spine fractures when switching to potent bisphosphonates after stopping denosumab.
NEJM Sep 6, 2026
Romosozumab improves shear bone strength in postmenopausal women with osteoporosis in BCT substudies
Drug Pipeline RCT
Romosozumab improves shear bone strength in postmenopausal women with osteoporosis in BCT substudies Romosozumab May Help Spinal Fusion Surgery Last Longer
This retrospective secondary analysis of phase 2 and 3 randomized trial data evaluated romosozumab in postmenopausal women with low bone den…
A bone drug may make spinal fusion surgery more secure for women with weak bones, new virtual tests suggest.
May 1, 2026
In male osteoporosis, anabolic therapies improved lumbar spine and hip BMD more than antiresorptives at 12 months
Diabetes & Endocrinology Meta-analysis
In male osteoporosis, anabolic therapies improved lumbar spine and hip BMD more than antiresorptives at 12 months Men Get Osteoporosis Too — and Now We Know Which Drugs Win
This Bayesian network meta-analysis evaluated antiresorptive and anabolic pharmacological interventions in men with osteoporosis.
A new analysis of 18 clinical trials finds that bone-building drugs may outperform bone-preserving drugs for men with osteoporosis, especial…
Frontiers Apr 10, 2026